Evidence map›Paper›PMID 25719760›Full record

ArticleACS combinatorial science2015

Design of high-throughput screening assays and identification of a SUMO1-specific small molecule chemotype targeting the SUMO-interacting motif-binding surface.

Aileen Y Alontaga, Yifei Li, Chih-Hong Chen, Chen-Ting Ma, Siobhan Malany, Danielle E Key, Eduard Sergienko, Qing Sun, David A Whipple, Daljit S Matharu and 7 more

Abstract read
In one paragraph

Article in ACS combinatorial science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Aileen Y Alontaga†Department of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, California 91010, United States.
Yifei Li†Department of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, California 91010, United States.
Chih-Hong Chen†Department of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, California 91010, United States.
Chen-Ting Ma‡Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Institute, La Jolla, California 92037, United States.
Siobhan Malany§Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Institute at Lake Nona, Orlando, Florida 32827, United States.
Danielle E Key§Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Institute at Lake Nona, Orlando, Florida 32827, United States.
Eduard Sergienko‡Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Institute, La Jolla, California 92037, United States.
Qing Sun‡Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Institute, La Jolla, California 92037, United States.
David A Whipple∥University of Kansas Specialized Chemistry Center, Lawrence, Kansas 66049, United States.
Daljit S Matharu∥University of Kansas Specialized Chemistry Center, Lawrence, Kansas 66049, United States.
Baozong Li†Department of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, California 91010, United States.
Ramir Vega†Department of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, California 91010, United States.
Yi-Jia Li†Department of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, California 91010, United States.
Frank J Schoenen∥University of Kansas Specialized Chemistry Center, Lawrence, Kansas 66049, United States.
Brian S J Blagg∥University of Kansas Specialized Chemistry Center, Lawrence, Kansas 66049, United States.
Thomas D Y Chung‡Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Institute, La Jolla, California 92037, United States.
Yuan Chen†Department of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, California 91010, United States.
Sanford Burnham Prebys Medical Discovery Institute · USBeckman Research InstituteUniversity of Kansas · USCity of Hope · US

Funding

Sanford-Burnham Center for Chemical GenomicsU54HG005033 · NHGRI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI JACKSON, MICHAEL · 2008 to 2012
$72.5M
University of Kansas Specialized Chemistry CenterU54HG005031 · NHGRI · UNIVERSITY OF KANSAS LAWRENCE · PI AUBE, JEFFREY · 2008 to 2013
$21.5M
SUMO modification and DNA damage response in cancer therapyR01GM086171 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, YUAN · 2008 to 2020
$5.2M
SENP:Conformational Dynamics and Inhibition by Small MoleculesR01GM102538 · NIGMS · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, YUAN · 2012 to 2015
$1.7M
Chemical Approaches to Protein Arginine MethylationR01GM086717 · NIGMS · UNIVERSITY OF GEORGIA · PI ZHENG, Y. GEORGE · 2010 to 2014
$1.2M
Avance II 500 High Performance Digital NMR Spectrometer SystemS10RR024664 · NCRR · UNIVERSITY OF KANSAS LAWRENCE · PI VANDERVELDE, DAVID G · 2007 to 2007
$468k
High Throughput Assays to Identify Inhibitors of SUMO-mediated Protein-Protein InR21NS066498 · NINDS · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, YUAN · 2009 to 2012
$208k
NCRR NIH HHS S10 RR024664NCRR NIH HHS S10RR024664NHGRI NIH HHS U54 HG005031NHGRI NIH HHS U54HG005031NHGRI NIH HHS U54 HG005033NIGMS NIH HHS R01 GM086171NIGMS NIH HHS R01 GM086717NIGMS NIH HHS R01GM086717NIGMS NIH HHS R01 GM102538NIGMS NIH HHS R01GM102538NINDS NIH HHS 1R21NS066498-01NINDS NIH HHS R21 NS066498
6 · The paper itself

Abstract

Protein-protein interactions are generally challenging to target by small molecules. To address the challenge, we have used a multidisciplinary approach to identify small-molecule disruptors of protein-protein interactions that are mediated by SUMO (small ubiquitin-like modifier) proteins. SUMO modifications have emerged as a target with importance in treating cancer, neurodegenerative disorders, and viral infections. It has been shown that inhibiting SUMO-mediated protein-protein interactions can sensitize cancer cells to chemotherapy and radiation. We have developed highly sensitive assays using time-resolved fluorescence resonance energy transfer (TR-FRET) and fluorescence polarization (FP) that were used for high-throughput screening (HTS) to identify inhibitors for SUMO-dependent protein-protein interactions. Using these assays, we have identified a nonpeptidomimetic small molecule chemotype that binds to SUMO1 but not SUMO2 or 3. NMR chemical shift perturbation studies have shown that the compounds of this chemotype bind to the SUMO1 surface required for protein-protein interaction, despite the high sequence similarity of SUMO1 and SUMO2 and 3 at this surface.

Indexed as

Fluorescence Resonance Energy TransferAmino Acid MotifsBinding SitesLigandsMagnetic Resonance SpectroscopyModels, MolecularProtein BindingProtein ConformationSmall Ubiquitin-Related Modifier ProteinsLigandsSmall Ubiquitin-Related Modifier Proteinsfluorescence polarizationsmall ubiquitin-like modifier (SUMO)SUMO-interacting motif (SIM)TR-FRET

Identifiers

PMID25719760
PMCPMC4609574
OpenAlexW2318354516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.